top of page
arrière plan G&CTI - gene and cell therapy institute



G & CTI Strategic Committee

An essential decision-maker to guide G & CTI's actions over the long term, the strategic committee owes its sagacity to the commitment of its members: office, general secretariat and college presidencies. In 2021, its support should allow the entire Think-Tank, now structured, to materialize its commitment to developing ideas and actions supporting its ambitions, already enshrined in its founding pillars. Thus, coordinated by its office and its general secretariat, G & CTI wants to make 2021 a year dedicated to the genesis of content and concrete solutions.


Comité stratégique




Co-Founder of Biotherapy Partners, Treasurer of SFTCG, Member of

Olivier NEGRE, PhD

Co-Founder of Biotherapy Partners, Treasurer of the SFTCG, Member of the Cure Sickle Cell Initiative

fond JS.png
fon ON.png
Olivier NEGRE

After an engineering degree from ENSTBB, I worked on the development of recombinant proteins for vaccines within the company BioProtein Technologies. I then prepared a doctorate in cellular and molecular biology in an INSERM laboratory before joining the bluebird bio company. For fifteen years, I worked in France and the United States, developing a gene therapy drug for the treatment of beta-thalassemia, from preclinical proof of concept, to clinical trials and upon placing on the market. I am co-founder of the company Biotherapy Partners, treasurer of the French Society of Cell and Gene Therapy, member of the Cure Sickle Cell Initiative in the USA and co-president of the G & CTI think-tank. This free and independent space for reflection brings together those involved in gene and cell therapy around a common objective, to make biotherapies accessible to all those who need them.

olivier negre président de G&CTI

University Professor - Hospital Practitioner, Prof. Jean Sibilia has been Dean of the Faculty of Medicine of Strasbourg since 2011 after having been Vice-President (2016-2018) then President of the National Conference of Deans (2018-2020) and Member of the National Health Conference since 2020. Having been president of the National Committee for the Coordination of Research from 2012 to 2016, he is now co-head of the National Reference Center for Systemic Autoimmune Diseases (Strasbourg University Hospital) and director Deputy of the Inserm Unit UMR_1109: Molecular Immuno-Rheumatology. He is also the medical director of an FHU project (Hospital-University Federation project) and, as President, leads the new FORCE foundation intended to support medical research.

He has been an elected member of the University of Strasbourg's CA since 2017 and a member of the Collegium Vie et Santé.
Prof. Sibilia was president of the Rheumatism and Inflammation Club (CRI), a CRI-IMIDIATE scientific cooperative group comprising more than 2000 investigators interested in autoimmune and auto-inflammatory diseases. He is responsible for the Inter-University Diplomas devoted to inflammatory rheumatism, autoimmune diseases, biomedicines and interventional rheumatology.

Editor of more than 400 scientific articles and numerous educational books devoted to inflammatory and autoimmune diseases. Prof. Sibilia is also a member of various learned societies (Société Française de Rhumatologie (SFR); European League Against Rheumatism (EULAR); American College of Rheumatology (ACR)) and honorary president of the Tunisian Anti-Rheumatism League (LITAR) .

Jean Sibilia président de G&CTI
illustration trésoriers g&cti bureau




Biopharmaceutical sector analyst and CEO BioPharmAnalyse


President and COO OctopussyX BioConsulting


It has now been about thirty years that I have been actively involved in the fields of biotechnologies and innovative therapies, first as a journalist for the specialized written press, then now as a consultant and manager of a digital platform. information and studies on the biopharmaceutical sector with a marked focus on the issues of cell therapy and gene therapy. My membership and my involvement within G & CTI are therefore a logical and obvious outcome to raise awareness of the challenges of these new treatments and contribute to their development and applications in France.


Anne-Lise Berthier trésorière g&cti
fond 2.png

Having a scientific background, I was quickly enthusiastic about the new paradigm represented by gene and cell therapies. After a few years in the laboratory, I had the opportunity for several years to ensure the technology watch department in a large French gene therapy laboratory. There, I acquired a mastery of the global technological panorama by being attentive to the most promising new developments, but also a knowledge of the players in the field and the evolution of their strategic positions and the global landscape. On the strength of these achievements and this particularly enriching and formative experience, I decided to create my own consulting entity at the service of companies in the innovative therapy sector.


Anne Marie.jpg


illustration BlueDil secrétaire général de G&CTI
BlueDil secrétaire général de G&CTI

Secretary General and founding member of the institute, BlueDil is committed to companies and organizations wishing to provide solutions to people suffering from serious illnesses and orphan illnesses.

With more than 60 years of experience in the field of orphan drugs and innovative therapies, BlueDil draws its strength and originality from the complementary skills of its team, reinforced by the expertise of its European network BlueDil International . Its goal is to help its clients bring innovative solutions to patients faster and help improve their lives.

BlueDil is able to lead a wide range of strategic & operational missions in France and in Europe, personalized and dimensioned to the exact measure of each mission, offering optimal efficiency on a European as well as local scale. In-depth knowledge of local ecosystems is a guarantee of success and ensures maximum compliance.

BlueDil offers a global and transversal vision of the world of rare diseases, from the field of market access, medical and commercial affairs, from the training of teams dedicated to these diseases, to the specifics of drug distribution. orphans.

bottom of page